Celcuity, Inc. $CELC Shares Bought by Wellington Management Group LLP

Wellington Management Group LLP raised its stake in Celcuity, Inc. (NASDAQ:CELC - Free Report) by 35.1% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 84,825 shares of the company's stock after purchasing an additional 22,049 shares during the period. Wellington Management Group LLP owned 0.22% of Celcuity worth $858,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also modified their holdings of the company. GAMMA Investing LLC grew its stake in shares of Celcuity by 1,237.4% during the first quarter. GAMMA Investing LLC now owns 1,324 shares of the company's stock worth $131,000 after acquiring an additional 1,225 shares during the last quarter. Aquatic Capital Management LLC purchased a new stake in shares of Celcuity during the fourth quarter worth about $50,000. Focus Financial Network Inc. purchased a new stake in shares of Celcuity during the first quarter worth about $108,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Celcuity during the fourth quarter worth about $142,000. Finally, Perkins Capital Management Inc. purchased a new stake in shares of Celcuity during the first quarter worth about $115,000. Hedge funds and other institutional investors own 63.33% of the company's stock.

Insider Transactions at Celcuity

In other Celcuity news, Director David Dalvey sold 100,000 shares of the business's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $43.98, for a total value of $4,398,000.00. Following the completion of the transaction, the director directly owned 125,000 shares of the company's stock, valued at approximately $5,497,500. The trade was a 44.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 15.77% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Needham & Company LLC dropped their price target on Celcuity from $74.00 to $70.00 and set a "buy" rating on the stock in a research note on Friday, August 15th. HC Wainwright boosted their price target on Celcuity from $50.00 to $66.00 and gave the stock a "buy" rating in a research note on Monday, August 18th. Stifel Nicolaus assumed coverage on Celcuity in a research note on Tuesday, July 1st. They set a "buy" rating and a $30.00 price target on the stock. Finally, Leerink Partners boosted their price target on Celcuity from $28.00 to $60.00 and gave the stock an "outperform" rating in a research note on Monday, July 28th. Four research analysts have rated the stock with a Buy rating, According to MarketBeat, Celcuity has an average rating of "Buy" and an average target price of $56.50.

Celcuity Stock Performance

NASDAQ CELC traded up $1.22 during trading hours on Friday, reaching $55.69. The stock had a trading volume of 831,391 shares, compared to its average volume of 916,796. The stock has a fifty day moving average of $34.32 and a 200 day moving average of $18.88. The stock has a market cap of $2.36 billion, a P/E ratio of -16.14 and a beta of 0.72. Celcuity, Inc. has a 52-week low of $7.57 and a 52-week high of $57.48. The company has a debt-to-equity ratio of 2.24, a quick ratio of 4.58 and a current ratio of 4.58.

Celcuity (NASDAQ:CELC - Get Free Report) last issued its earnings results on Thursday, August 14th. The company reported ($1.04) EPS for the quarter, missing analysts' consensus estimates of ($0.90) by ($0.14). Sell-side analysts predict that Celcuity, Inc. will post -2.62 earnings per share for the current year.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.